Analysts at StockNews.com started coverage on shares of vTv Therapeutics (NASDAQ:VTVT – Get Rating) in a research report issued on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Separately, Northland Securities raised their target price on shares of vTv Therapeutics from $1.50 to $2.00 and gave the company an “outperform” rating in a report on Wednesday, August 17th.
vTv Therapeutics Stock Performance
VTVT stock opened at $0.79 on Thursday. The firm has a fifty day moving average price of $0.90 and a 200 day moving average price of $0.85. vTv Therapeutics has a fifty-two week low of $0.38 and a fifty-two week high of $1.40. The firm has a market cap of $82.62 million, a PE ratio of -2.63 and a beta of -1.26.
Institutional Inflows and Outflows
About vTv Therapeutics
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis.
- Get a free copy of the StockNews.com research report on vTv Therapeutics (VTVT)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.